Metformin monotherapy is an effective alternative for management of gestational diabetes mellitus in patients refusing insulin monotherapy by Russeth, Tyler
Clinical Research in Practice: The Journal of 
Team Hippocrates 
Volume 7 Issue 2 Article 15 
2021 
Metformin monotherapy is an effective alternative for 
management of gestational diabetes mellitus in patients refusing 
insulin monotherapy 
Tyler Russeth 
Wayne State University School of Medicine, gm7353@wayne.edu 
Follow this and additional works at: https://digitalcommons.wayne.edu/crp 
 Part of the Medical Education Commons, and the Translational Medical Research Commons 
Recommended Citation 
RUSSETH T. Metformin monotherapy is an effective alternative for management of gestational diabetes 
mellitus in patients refusing insulin monotherapy. Clin. Res. Prac. Oct 13 2021;7(2):eP2863. 
https://doi.org/10.22237/crp/1622161140 
This Clinical Decision Report is brought to you for free and open access by the Open Access Journals at 
DigitalCommons@WayneState. It has been accepted for inclusion in Clinical Research in Practice: The Journal of 
Team Hippocrates by an authorized editor of DigitalCommons@WayneState. 
 
VOL 7 ISS 2 / eP2863 / OCTOBER 13, 2021  
https://doi.org/10.22237/crp/1622161140 
 




http://digitalcommons.wayne.edu/crp, © 2021 The Author(s) 
1 Licensed under Creative Commons Attribution 4.0 International (CC-BY-4.0) 
 
Metformin monotherapy is an effective 
alternative for management of gestational 
diabetes mellitus in patients refusing 
insulin monotherapy 
TYLER RUSSETH, Wayne State University School of Medicine, gm7353@wayne.edu 
 
ABSTRACT A clinical decision report using: 
Ghomian N, Vahed SHM, Firouz S, Yaghoubi MA, Mohebbi M, Sahebkar A. The efficacy of metformin compared with insulin in 
regulating blood glucose levels during gestational diabetes mellitus: A randomized clinical trial. J Cell Physiol. 2019;234(4):4695-
4701. https://doi.org/10.1002/jcp.27238 
for a patient with gestational diabetes mellitus (GDM) who does not wish to undergo insulin monotherapy. 
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Clinical-Social Context 
Linda Johnson (pseudonym) is a 27-year-old, G2P1001 African American woman at 25 and 4/7 weeks gestation, 
that presented to the high-risk obstetric clinic following a recent diagnosis of gestational diabetes mellitus (GDM) 
by a positive 75g glucose tolerance test (GTT) at 24 weeks gestation. Her past medical history included a prior 
cesarean delivery due to poorly controlled GDM as well as severe asthma. Upon talking to Ms. Johnson, she 
expressed that she was “very disappointed and worried” that she had been diagnosed with GDM for her second 
pregnancy. She stated that this happened during her first pregnancy and she took insulin to control her sugar but 
that she had a difficult time injecting the insulin due to pain and a fear of needles. She said that “taking insulin was 
the worst thing in the world” and she eventually stopped, leading to fetal macrosomia, prompting a cesarean 
delivery which was particularly “traumatizing.” Following Mrs. Johnson’s positive GTT test, her low-risk obstetrician 
recommended a diet and exercise intervention for one week, but she had been unable to make necessary changes. 
She said that she improved her diet but cannot exercise due to her severe asthma that has worsened during 
pregnancy. At her clinic visit, she had a fasting glucose of 103.5 mg/dl, indicating her glucose was still not well 
controlled. She asked, “I know metformin is for regular diabetes, but can I use it for pregnancy diabetes too?” She 
emphasized the fact that she would refuse to use insulin again but also did not want to undergo another cesarean 
delivery. 
Of note, Mrs. Johnson said that she has ample access to healthy food options at the local store and has a driver’s 
license and car for transportation. She does not currently work but her husband has a secure job at Ford Motor 
Company and can support the family’s financial needs. She lives in a single-story townhouse with her husband and 
3-year-old son and feels very safe at home and in the community. 
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Clinical Question 
Is metformin monotherapy as efficacious as insulin monotherapy (gold standard) for management of gestational diabetes mellitus 
(GDM) for prevention of fetal macrosomia and risk of cesarean delivery? 
Research Article 
Ghomian N, Vahed SHM, Firouz S, Yaghoubi MA, Mohebbi M, Sahebkar A. The efficacy of metformin compared with insulin in 
regulating blood glucose levels during gestational diabetes mellitus: A randomized clinical trial. J Cell Physiol. 2019;234(4):4695-
4701. https://doi.org/10.1002/jcp.27238 1 
Description of Related Literature 
Collection of related information began with searching “gestational diabetes management” on The American College of Obstetrics 
and Gynecology (ACOG) to view current guidelines. At present, ACOG recommends pharmacologic treatment when target glucose 
levels cannot be achieved through nutrition and exercise. First line pharmacologic treatment is insulin with second line being oral 
antidiabetic medications (metformin and glyburide).2 One randomized control trial (RCT) was mentioned that directly compared 
insulin versus metformin with primary outcome measures being neonatal hypoglycemia and maternal glucose levels.3 The study 
demonstrated equivalent efficacy of metformin to insulin but did not measure fetal macrosomia and risk for cesarian delivery which 
is Mrs. Johnson’s main concern. 
Additional literature review was performed on PubMed with an initial search using the key words “gestational diabetes [title] and 
metformin and insulin” which yielded 239 results and after filtering for RCTs, 35 articles remained. Seventeen of these articles were 
removed due to being unrelated to the question in focus. Two studies were removed due to comparing metformin to placebo rather 
than insulin.4-5 A number of studies focused on the direct comparison of metformin versus insulin therapy for GDM. However, many 
were removed due to measuring unrelated outcomes such as markers of metabolic status (triglycerides, lipids, and A1c levels),6-8 
inflammatory markers,9 and B12 levels10. Several RCTs had primary outcomes focusing on fetal macrosomia and cesarian delivery 
but were not chosen for clinical use because upwards of 46.3% of study participants in the metformin group received supplemental 
insulin to achieve euglycemia.11-17 Mrs. Johnson has attempted and failed insulin therapy in the past and refuses to consider insulin 
use for this pregnancy.  
Moore et al.18 published their preliminary results for a prospective randomized control trial investigating metformin and insulin as 
therapeutic options for GDM. 63 participants were randomly placed in either intervention group following a positive 75g GTT test 
and that failed a 2-week trial of diet and lifestyle interventions. No participants in the metformin group required supplemental 
insulin. Preliminary results demonstrated no statistical difference in rate of cesarian delivery or neonate birth weight, suggesting 
metformin is a promising option. This study was ultimately not chosen due to the limited sample size, availability of only preliminary 
results, and two-week trial of diet and lifestyle rather than a one-week trial like Mrs. Johnson. 
The randomized control trial chosen for appraisal was a study conducted by Ghomian et al.1 The study randomly assigned 286 
pregnant women that were diagnosed with GDM following a 75g GTT and failed a 1-week trial of diet and exercise, to either insulin 
or metformin monotherapy. Of note, patients with a prior history of overt diabetes mellitus were not included in the study. If a 
patient in the metformin group required supplemental insulin, they were removed from the study and replaced with another study 
participant. The study concluded that there was no statistical difference between the two groups for birth weight, birth trauma, and 
rate of cesarean delivery. The article’s findings are similar to the findings of the previously reviewed papers and best captures the 
efficacy of metformin alone in management of GDM. This study was selected because it is the only available paper that examines 
metformin therapy without the use of supplemental insulin, best correlating to Mrs. Johnson’s desire for therapeutic options that do 
not include insulin.  
According to the strength of recommendation taxonomy (SORT), this study achieves a category B grade Strength of 
Recommendation due to the lack of at least two other good quality RCTs with consistent findings.19 Currently, Moore et al.18 is the 
only other paper that examines metformin monotherapy without use of supplemental insulin. 
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Critical Appraisal 
The study by Ghomian et al.1 is a multicenter, randomized clinical trial that recruited patients from three academic hospitals 
affiliated with Mashad University of Medical Sciences in Iran. A total of 286 participants aged 18 to 40 (mean = 28.36 years) with a 
gestational age over 24 weeks and recently diagnosed with GDM via a positive 75g GTT were recruited (mean = 24.95 weeks 
gestation at diagnosis). Additional inclusion criteria included singleton pregnancy, failure to achieve glycemic control with diet and 
exercise, absence of diabetes mellitus and other medical diseases. Exclusion criteria included refusal to follow up and not responding 
to the maximal dose of 1500mg metformin to better evaluate the effects of metformin by itself. Once selected, patients were 
randomly assigned to receive insulin (gold standard) or metformin. Both study groups were similar in age, body mass index, previous 
history of GDM, and gestational age at treatment onset. Glycemic control goals were fasting plasma glucose <95 mg/dl and 2hr 
postprandial glucose <120mg/dl. All patients followed up every 2 weeks to receive a fasting and 2hr postprandial plasma glucose 
(FPG and 2-hr PG) measurement and subsequent dosage adjustment if necessary, to meet goal glucose values. Patients were 
followed until delivery. The study was not blinded due to the nature of administration of the two therapies, oral pill versus injection; 
however, the outcome assessor and data analyst were blinded to treatment groups. According to SORT criteria, this would be 
considered level 1 evidence.19 
The primary outcomes assessed in the study were FPG, 2-hr PG, preterm birth, Apgar score, birth weight, birth trauma, admission to 
NICU, and mode of delivery (vaginal or cesarean). Inferential analysis (student’s t test and the χ2 test) found no statistical difference 
between the two groups (insulin vs. metformin) in any of the measured primary outcomes. Average neonate birth weight was 3450 
± 548g and 3544 ± 57g for the metformin and insulin group, respectively (p = 0.15). 25 (42.9%) and 24 (38.5%) of the patients from 
the metformin and insulin groups, respectively, underwent cesarean delivery (X2 = 0.887; p=0.642).  
Mrs. Johnson is well represented in the sampled participants because she has a similar age, gestational age at GDM diagnosis, and 
baseline glucose values and meets all inclusion criteria for this study. Additionally, 34% of the metformin group had a prior history of 
GDM. The primary outcomes evaluated address her concerns of neonate weight and necessity of cesarian delivery for metformin 
therapy.  
Participants were recruited upon diagnosis of GDM. There is small attrition bias as only 8.7% (n=20 metformin and n=10 insulin) of 
participants were lost at some point during their 2-week follow-ups. There is no indication bias as both treatment groups had a 
similar BMI, family history of diabetes, history of prior GDM, and baseline glucose levels at treatment onset. Lastly, there was no 
apparent funding bias. The study was funded by a grant from the university and the authors did not declare any conflicts of interest. 
Additional strengths of the study include large sample size and consistent treatment protocol for both arms of treatment.   
The appraised study is prone to selection bias as participants that failed metformin monotherapy were excluded from the study and 
replaced with new participants. There may be an underlying reason why this group is unable to maintain target glycemic values on 
metformin alone, concealing a confounding variable. This is the single biggest methodological flaw of the study. Yet, if this is kept in 
mind when attempting to counsel Mrs. Johnson, we are able to use the evidence presented to make clinical decisions. We wanted a 
study evaluating metformin without supplemental insulin and this is the only piece of literature that examines this. Additionally, the 
study may be prone to performance bias as the study was not double blinded. The performance bias could lead to differences in 
study participant compliance to therapy or physician interactions during routine checkups. However, the study focuses on objective 
measures for therapy adjustments (FPG and 2-hr PG) and for mode of delivery (e.g. fetal weight and fetal heart tracings) which can 
mitigate this source of bias. The outcome assessor, the individual at delivery, was blinded. Another weakness in the paper is the 
study location. The study was performed in Iran and all participants are presumptively from surrounding areas and are not African 
American. The ethnicity and diet and lifestyle of the study participants differ from Mrs. Johnson living in a metropolitan area. The 
difference in culture or surrounding food options might contribute to varying difficulty in managing GDM on metformin alone. 
Clinical Application 
Mrs. Johnson wanted to know if metformin rather than standard insulin therapy would be a good option for 
managing her GDM, especially in prevention of fetal macrosomia and cesarean delivery. Her preference stems 
from her bad experience during her first pregnancy and refusal to continue insulin. Based on the findings of the 
appraised article, Mrs. Johnson was informed that metformin is a good alternative to insulin therapy and that 
either therapy, when followed correctly, can manage her GDM and prevent fetal complications and risk for 
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cesarian delivery. However, she was informed that a small percentage of patients still cannot adequately control 
their GDM through metformin alone and that insulin therapy might need to be reconsidered in the future. It was 
emphasized that she needs to regularly follow up with the clinic every 2 weeks to check her glucose levels and 
adjust metformin dosages as needed. Mrs. Johnson was happy that we were willing to try metformin therapy and 
understood that she cannot miss any future doctor appointments and that the therapy may not work for her for 
unknown reasons. 
New Knowledge Related to Clinical Decision Science 
Mrs. Johnson’s reluctance of insulin therapy for management of her GDM led to the clinical team exploring other therapeutic 
options that could achieve euglycemia and prevent maternal and fetal complications. While not first line therapy, metformin is a 
great alternative for Mrs. Johnson. This clinical scenario illustrates the interplay between the patient and physician when making 
clinical decisions. The healthcare team needs to listen and fully understand the patient’s healthcare wishes, especially when 
choosing treatment plans. If the patient is ignored, they may not be willing to adhere with any treatment, possibly leading to further 
complications down the road. In fact, Mrs. Johnson told us that is exactly what happened with her previous pregnancy.  
Mrs. Johnson’s preferences originate from a poor experience with insulin therapy due to the nature of frequent injections with 
needles. In her case, why not try a second line therapy if it demonstrates equivalent efficacy and avoids the use of needles? She is 
willing to be compliant and has the necessary transportation resources for frequent checkups. Worst case she fails metformin 
therapy, and her physicians must sit down and reassess her ability to adhere to insulin therapy. But at least another therapy was 
attempted. Other efficacious therapeutic options should always be explored based on the patient’s distinct social context or 
personal experience.  
The question that Clinical Decision Science needs to explore is situations where the recommendations of the physician and the 
willingness of the patient to accept those recommendations are at odds. How far are physicians willing to support “poor decisions” 
of patients by participating in sub-optimal treatment plans. This issue frequently occurs when doctors must face whether to provide 
treatment to patients who leave the hospital against medical advice. Do physicians become “co-dependent” to unhealthy behavior 
or are they honoring the agency of the patient to choose treatment for themselves. These types of decisions also occur frequently in 
end-of-life decisions. Understanding the various contributing factors in how such decision are made is the task for Clinical Decision 
Science.  
In this Decision Report, the doctors took the time and effort to find evidence to support the patient’s decision, convincing 
themselves it was an appropriate management plan—one that worked for both the patient and the treatment team. 
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